Alder Biopharmaceuticals Inc Watch

from 8-K 19 pages Alder Biopharmaceuticals, Inc. Executive Severance Benefit Plan

from 8-K 9 pages This Letter Agreement (This “Agreement”) Confirms the Understanding Between You and Alder Biopharmaceuticals, Inc. (The “Company”) Regarding Certain Treatment That You May Become Entitled to Receive in Connection With the Acquisition (The “Acquisition”) of the Company by H. Lundbeck a/S (“Parent”), Pursuant to That Certain Agreement and Plan of Merger, Dated as of September 16, 2019, Among the Company, Parent and Certain Other Parties (The “Merger Agreement”). Capitalized Terms Used but Not Otherwise Defined in This Letter Have the Meanings Given to Such Terms in the Merger Agreement. This Agreement Will Become Effective Immediately Prior to the Offer Acceptance Time. However, if the Merger Agreement Terminates Pursuant to Its Terms or Your Employment With the Company Terminates for Any Reason Prior to the Offer Acceptance Time, This Letter Will Terminate and Be of No Force or Effect. 1. Certain Taxes

from 10-Q 9 pages Alder Biopharmaceuticals, Inc. Non-Employee Director Stock Option Grant Notice

from 10-Q 9 pages Alder Biopharmaceuticals, Inc. Non-Employee Director Stock Option Grant Notice

from 10-Q 10 pages Alder Biopharmaceuticals, Inc. 2018 Inducement Award Plan Restricted Stock Unit Award Grant Notice

from 10-Q 22 pages Alder Biopharmaceuticals, Inc. 2018 Inducement Award Plan Adopted by the Compensation Committee: June 11, 2018 Amended and Restated by the Compensation Committee: June 20, 2019

from 10-Q 1 page Alder Biopharmaceuticals, Inc. Non-Employee Director Compensation Information

from 10-Q 32 pages March 28, 2019 John A. Latham, PH.D. Re:transition and Consulting Agreement

from 8-K 47 pages Common Stock Purchase Agreement

from 10-K 73 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Is Filed With the Securities and Exchange Commission Pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as Amended

from 10-K 8 pages Confidential

from 10-K 4 pages Confidential

from 10-K 5 pages Confidential

from 10-K 4 pages Confidential

from 10-K 4 pages Confidential

from 10-K 51 pages Confidential

from 10-K 2 pages February 7, 2019 Carlos E. Campoy Re: Amendment to Offer of Employment at Alder Biopharmaceuticals, Inc. (The “Company” or “Alder”) Dated December 4, 2018

from 10-K 2 pages • Compensation: Your Position Is Classified as Exempt for Purposes of Wage and Hour Laws. Your Starting Salary Will Be $410,000.00 Annually, Which Will Be Paid on a Monthly Basis. You Will Also Be Eligible for a 40% Target Bonus Starting With the 2019 Calendar Year. a Salary Review Will Take Place Annually, and Will Be Linked to an Evaluation Process. Your First Salary Review Will Take Place in January 2020

from 10-K 14 pages November 2, 2018 Elisabeth A. Sandoval, M.B.A. via Email and Docusign Re:transition Agreement Dear Elisabeth

from 8-K 47 pages Distribution Agreement